{"product_id":"inmb-vrio-analysis","title":"INmune Bio, Inc. (INMB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to INmune Bio, Inc. (INMB)'s market position with this concise VRIO analysis, where we rigorously test its core resources for Value, Rarity, Inimitability, and Organization. Discover immediately whether this business possesses a sustainable competitive advantage or if its strengths are easily replicated. Read on below to see the distilled verdict on what truly drives INmune Bio, Inc. (INMB)'s success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: DN-TNF (XPro™) Platform Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at INmune Bio, Inc.’s XPro™ platform, which aims to hit soluble TNF (sTNF) in Alzheimer’s disease (AD). Honestly, the data from the Phase 2 MINDFuL trial is a classic biotech mixed bag: the overall study missed its primary goal, but a specific, targeted group showed real promise. That’s where the real value lies right now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Targeting Inflammation in Early AD\u003c\/h3\u003e\n\u003cp\u003eThe platform is definitely valuable because it targets sTNF, which the company posits is a key driver of neuroinflammation in AD. The market need here is enormous, even with recent approvals in the space. The proof is in the subgroup data from the MINDFuL trial: in the biomarker-enriched ADi population (amyloid-positive patients with \u003cstrong\u003etwo or more\u003c\/strong\u003e inflammation biomarkers, n=\u003cstrong\u003e100\u003c\/strong\u003e), XPro™ showed consistent positive trends. Specifically, we saw a slowed cognitive decline on the EMACC with an effect size of \u003cstrong\u003e0.27\u003c\/strong\u003e, and a reduction in neuropsychiatric symptoms on the NPI with an effect size of \u003cstrong\u003e-0.23\u003c\/strong\u003e. Plus, they saw a biological benefit on pTau217 (effect size \u003cstrong\u003e-0.18\u003c\/strong\u003e) and, crucially, a complete absence of amyloid-related imaging abnormalities (ARIA). That safety profile is a big deal.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the ADi population benefit:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEMACC (Cognition): Effect Size \u003cstrong\u003e0.27\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNPI (Behavior): Effect Size \u003cstrong\u003e-0.23\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003epTau217 (Biomarker): Effect Size \u003cstrong\u003e-0.18\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis technology selectively neutralizes sTNF without touching trans-membrane TNF (tmTNF). That precision is what makes it potentially valuable.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Selective Mechanism of Action\u003c\/h3\u003e\n\u003cp\u003eThe approach is likely rare because it uses dominant-negative technology to selectively neutralize sTNF. Most existing TNF inhibitors are broader. This specificity - hitting the soluble form while sparing the membrane-bound form - is a distinct chemical and biological maneuver. What this estimate hides is how many other companies are close to a similar selective sTNF inhibitor that could reach the market sooner.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Complexity of Design\u003c\/h3\u003e\n\u003cp\u003eImitating this is difficult, frankly. It requires deep, specialized knowledge of TNF biology and very complex drug design to achieve that selectivity. You can’t just copy the structure; you need the underlying scientific know-how. Still, as the field matures, the barrier to entry for next-generation TNF modulators might drop, but for now, it’s a high bar.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Data and Financial Standing\u003c\/h3\u003e\n\u003cp\u003eOrganization is moderate. They have compelling Phase 2 data in a prespecified, high-need subgroup, which is a huge step. They are moving to translate this into regulatory action, planning to submit for Breakthrough Therapy designation with the FDA. Financially, as of September 30, 2025, INmune Bio, Inc. held approximately \u003cstrong\u003e$27.7 million\u003c\/strong\u003e in cash and cash equivalents. Their market capitalization was around \u003cstrong\u003e$51 million\u003c\/strong\u003e as of October 30, 2025. They need capital to push this through, so the organization’s ability to secure further funding is critical to realizing the technology’s potential.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage: Temporary Potential\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003etemporary\u003c\/strong\u003e. The science is promising, especially in the ADi cohort, but without a clear, approved path to market, the advantage isn't sustained. The market is watching for that FDA designation and subsequent Phase 3 design. If onboarding takes 14+ days, churn risk rises in these early-stage trials, which is a constant organizational hurdle in biotech.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of the VRIO assessment for the DN-TNF (XPro™) Platform:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data\/Observation (2025 Data)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePositive trends in ADi subgroup (n=\u003cstrong\u003e100\u003c\/strong\u003e) on EMACC (Effect Size \u003cstrong\u003e0.27\u003c\/strong\u003e); No ARIA observed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eLikely Yes\u003c\/td\u003e\n\u003ctd\u003eSelective neutralization of soluble TNF (sTNF) only; distinct from broad-spectrum TNF inhibitors.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eRequires deep expertise in TNF biology and complex dominant-negative drug design.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003ePhase 2 data in enriched population; Cash position of \u003cstrong\u003e$27.7M\u003c\/strong\u003e as of 9\/30\/2025; Market Cap of \u003cstrong\u003e$51M\u003c\/strong\u003e as of 10\/30\/2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003ePromising science, but sustained advantage hinges on regulatory success (e.g., Breakthrough Therapy submission).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: INKmune™ Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eINKmune™ Platform Technology\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Yes, it converts resting NK cells into persistent, tumor-killing mlNK cells, offering a tumor-agnostic cancer therapy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003emlNK cells persisted for more than \u003cstrong\u003e100 days\u003c\/strong\u003e in patients.\u003c\/li\u003e\n\u003cli\u003eFunctionality in hypoxic TME due to upregulated nutrient receptors and mitochondrial survival proteins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; the ability to create memory-like NK cells that function in the hypoxic tumor microenvironment (TME) is not common.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eINKmune priming upregulates 141 proteins unique compared to IL-12, IL-15, and IL-18 cytokine cocktail.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly; replicating the specific cell line and priming mechanism is complex and time-consuming.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePriming signals are akin to treatment with at least three cytokines in combination.\u003c\/li\u003e\n\u003cli\u003eINKmune™ is stable at \u003cstrong\u003e-80°C\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Good; Phase I safety endpoint met, and they are advancing the Phase II trial in metastatic castration-resistant prostate cancer.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase I\/II 'CaRe PC' trial met primary endpoint (safety) and is closed to enrollment.\u003c\/li\u003e\n\u003cli\u003eScientific Review Committee (SRC) unanimously voted to open all Phase II cohorts.\u003c\/li\u003e\n\u003cli\u003eTrial has a Bayesian design with three ascending dose cohorts.\u003c\/li\u003e\n\u003cli\u003eOver 20 infusions of INKmune given safely without conditioning therapy across MDS\/AML and mCRPC trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; if the persistence data holds, this unique mechanism offers a strong, hard-to-replicate edge.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNK cell function sustained for more than \u003cstrong\u003e40 days\u003c\/strong\u003e after the final INKmune® infusion in the lowest dose cohort.\u003c\/li\u003e\n\u003cli\u003eObserved in some patients, individual tumor lesions were reducing in size or completely disappearing during treatment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Metric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Timeframe\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Efficacy (Persistence)\u003c\/td\u003e\n\u003ctd\u003emlNK Cell Persistence in Patients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026gt;100 days\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIn patients treated with INKmune™\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Status (mCRPC)\u003c\/td\u003e\n\u003ctd\u003ePhase I Endpoint Met\u003c\/td\u003e\n\u003ctd\u003eSafety\u003c\/td\u003e\n\u003ctd\u003eCaRe PC Trial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trial Dosing\u003c\/td\u003e\n\u003ctd\u003eDose Levels Assessed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLow ($1 \\times 108$), Medium ($3 \\times 108$), High ($5 \\times 108$ cells\/infusion)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-clinical Efficacy (DU145)\u003c\/td\u003e\n\u003ctd\u003eResting NK Cell Kill Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\u0026lt;4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4 hours against DU145 cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-clinical Efficacy (DU145)\u003c\/td\u003e\n\u003ctd\u003eINKmune Primed NK Cell Kill Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~66%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e4 hours against DU145 cells\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.37 Million USD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$49.98 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 4, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Health\u003c\/td\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (LTM)\u003c\/td\u003e\n\u003ctd\u003eOperating Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$42.63M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Performance (LTM)\u003c\/td\u003e\n\u003ctd\u003eEarnings Per Share (EPS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-2.11\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLast 12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: CORDStrom™ Platform Technology\n\u003c\/h2\u003e\n\u003cp\u003eCORDStrom™ Platform Technology\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Yes, it offers a proprietary, allogeneic hucMSC platform for treating rare diseases like recessive dystrophic epidermolysis bullosa (RDEB). CORDStrom™ shows promise as a first systemic therapy for potentially treating RDEB.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; allogeneic MSCs exist, but the specific pooled, proprietary formulation is less common. The platform leverages proprietary screening, pooling and expansion techniques.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the cell source is common, but the specific manufacturing and pooling process is proprietary. The company received a favorable written opinion from The United States Patent and Trademark Office (USPTO) on all claims in its international patent application PCT\/US25\/17028, titled “THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS.”\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong; they completed pilot-scale manufacturing runs and are targeting regulatory filings mid-2026. The company announced successful completion of first two commercial pilot-scale manufacturing runs of CORDStrom™ at CGT Catapult in preparation of regulatory filings.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; strong organization around manufacturing gives them a lead, but regulatory success is the ultimate test.\u003c\/p\u003e\n\u003cp\u003eKey operational and financial metrics supporting the Organization and Value components:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Pilot Manufacturing Runs\u003c\/td\u003e\n\u003ctd\u003eTwo\u003c\/td\u003e\n\u003ctd\u003eCompleted at CGT Catapult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAA Submission Target (UK)\u003c\/td\u003e\n\u003ctd\u003eMid-2026\u003c\/td\u003e\n\u003ctd\u003eTarget\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBLA Filing Target (FDA)\u003c\/td\u003e\n\u003ctd\u003eShortly thereafter (after Mid-2026)\u003c\/td\u003e\n\u003ctd\u003eAnticipated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss Attributable to Common Stockholders\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Research and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp from $14,000 in Q3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePhase 2 trial results for CORDStrom™ in RDEB indicated potential therapeutic benefits:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImprovements observed in itch scores.\u003c\/li\u003e\n\u003cli\u003eImprovements observed in pain scores.\u003c\/li\u003e\n\u003cli\u003eImprovements observed in wound scores.\u003c\/li\u003e\n\u003cli\u003eImprovements observed in quality of life for RDEB patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Intellectual Property Portfolio (Especially CORDStrom™ Patents)\n\u003c\/h2\u003e\n\u003cp\u003eThe CORDStrom™ platform is described as a patent-pending cell medicine comprising aseptic, allogeneic, pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs) in suspension for injection or infusion.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eSecures exclusive rights for CORDStrom™ platform technologies. If granted, the patent is expected to secure IP exclusivity through at least \u003cstrong\u003e2045\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eA favorable written opinion was issued by the United States Patent and Trademark Office (USPTO) on April 8, 2025, concerning international patent application \u003cstrong\u003ePCT\/US25\/17028\u003c\/strong\u003e, validating all claims for patentability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFavorable Written Opinion Date: \u003cstrong\u003eApril 8, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eApplication Title: “THERAPEUTIC COMPOSITIONS COMPRISING POOLED, CULTURE-EXPANDED HUMAN UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS.”\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eLegal blocking of direct imitation is established through the patent process, projecting exclusivity until \u003cstrong\u003e2045\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company is utilizing the IP status to drive specific regulatory timelines for CORDStrom™ in Recessive Dystrophic Epidermolysis Bullosa (RDEB).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePlanned MAA Submission (RDEB): Mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated BLA Filing (RDEB): Shortly after mid-\u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 R\u0026amp;D Expenses: Approximately \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe projected exclusivity period provides a significant legal barrier to entry for competitors utilizing similar pooled hucMSC technology.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected IP Exclusivity End\u003c\/td\u003e\n\u003ctd\u003eAt least \u003cstrong\u003e2045\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUpon Grant\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$6.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eQuarter Ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Equivalents\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$27.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Shares Outstanding\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e26.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of October 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Clinical Data Package (Enriched Population Focus)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Yes, the Phase 2 MINDFuL data showing benefit in the inflamed, biomarker-positive AD subset validates the mechanism.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; demonstrating efficacy in a pre-defined, inflamed subset of AD patients is a rare, actionable data point.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; competitors cannot easily replicate the specific trial design or the resulting patient data.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; they are submitting the manuscript for peer review, showing intent to validate the findings externally.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the data is valuable, but it needs to be reinforced by further trials to become sustained.\u003c\/p\u003e\n\u003cp\u003eThe clinical package centers on the Phase 2 MINDFuL trial (NCT05318976) for XPro™ in early Alzheimer's Disease (AD) with inflammation.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Trial Enrollment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e208\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eParticipants in the Phase 2 MINDFuL trial.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003emITT Population\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en=200\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModified Intent-to-Treat population for primary endpoint analysis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnriched Population (ADi)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003en=100\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAmyloid-positive early AD patients with $\\geq$\u003cstrong\u003e2\u003c\/strong\u003e inflammatory biomarkers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMACC Effect Size (ADi)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.27\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCognitive benefit observed over placebo in the enriched population.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003epTau217 Effect Size (ADi)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-0.20\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBiological benefit observed over placebo in the enriched population.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARIA Occurrence\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eComplete absence\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNo Amyloid-Related Imaging Abnormalities (ARIA-E or ARIA-H) observed.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPOE $\\epsilon$4 Carriers (Baseline)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePercentage of participants carrying at least one APOE $\\epsilon$4 allele.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe submission of the manuscript detailing these results to \u003cstrong\u003enpj Dementia, a Nature Portfolio journal\u003c\/strong\u003e, supports external validation efforts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company anticipates receiving regulatory feedback from the FDA in the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company intends to file for Breakthrough Therapy Designation with the FDA based on the data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context relevant to sustaining organizational efforts includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003eMarch 31, 2025\u003c\/strong\u003e: approximately \u003cstrong\u003e$19.3 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash on Hand as of \u003cstrong\u003eJune 2025\u003c\/strong\u003e: \u003cstrong\u003e$33.37 Million USD\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for Q1 2025: approximately \u003cstrong\u003e$7.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDebt \/ Equity ratio: \u003cstrong\u003e0.04\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Manufacturing Readiness for CORDStrom™\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e \u003cstrong\u003eYes\u003c\/strong\u003e, successful pilot-scale manufacturing runs at CGT Catapult de-risks the path to commercialization for RDEB. CORDStrom™ is designed to address the severe unmet systemic needs of RDEB patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e \u003cstrong\u003eModerate\u003c\/strong\u003e; securing a partnership and completing initial commercial-scale runs for a cell therapy is a significant hurdle cleared. The platform leverages proprietary screening, pooling, and expansion techniques.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e \u003cstrong\u003eDifficult\u003c\/strong\u003e; establishing validated, scalable processes with a specialized CDMO partner takes time and capital. The successful runs confirm scalability and consistency utilizing a proprietary process to ensure high-quality, GMP-compliant product.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e \u003cstrong\u003eStrong\u003c\/strong\u003e; this operational success directly supports the \u003cstrong\u003emid-2026\u003c\/strong\u003e filing target.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e \u003cstrong\u003eTemporary\u003c\/strong\u003e; it’s an operational lead, but other firms can contract with other CDMOs.\u003c\/p\u003e\n\n\u003ch3\u003eOperational and Financial Context for CORDStrom™ Readiness\u003c\/h3\u003e\n\u003cp\u003eThe manufacturing progress is a critical step toward the targeted regulatory submissions for CORDStrom™ in Recessive Dystrophic Epidermolysis Bullosa (RDEB).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePilot Runs Completed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommercial scale at CGT Catapult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK MAA Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFirst half of 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS BLA Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMid-2026\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnticipated shortly after UK MAA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Net Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQuarter ended September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand (9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinancial performance and cash position provide a temporal context for executing the regulatory plan:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet loss attributable to common stockholders for Q3 2025 was approximately \u003cstrong\u003e$6.5 million\u003c\/strong\u003e, compared to approximately \u003cstrong\u003e$12.1 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses for Q3 2025 totaled approximately \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and equivalents stood at \u003cstrong\u003e$27.7 million\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company's cash position, based on its operating plan at the time of Q2 2025 reporting, was projected to fund operations into \u003cstrong\u003eQ3 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Innate Immune System Focus\/Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eInnate Immune System Focus\/Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Yes, it provides a unifying scientific strategy across three distinct therapeutic areas (AD, Cancer, Rare Disease). The Company is developing novel therapies that reprogram a patient's innate immune system to fight disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Moderate; many firms target immunity, but a deep, consistent focus on the innate immune system is more specialized. Drug candidates include INKmune™ and INB03 for cancer, and XPro1595 for Alzheimer's disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Moderate; the knowledge base is built over time, making it hard to replicate quickly. Dr. Barnum has been working with XPro1595 for more than a decade.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Good; the entire pipeline is structured around this central theme. The pipeline includes CORDStrom™, DN-TNF Platform (XPro™\/XPro1595), and INKmune™.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; this deep, specialized scientific focus forms the foundation of their R\u0026amp;D engine. The company's Q3 2025 reported EPS was \u003cstrong\u003e-$0.24\u003c\/strong\u003e, exceeding analyst expectations of \u003cstrong\u003e-$0.32\u003c\/strong\u003e by \u003cstrong\u003e25.00%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePlatform\/Focus Area\u003c\/th\u003e\n\u003cth\u003eTherapeutic Area(s)\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCORDStrom™\u003c\/td\u003e\n\u003ctd\u003eRecessive Dystrophic Epidermolysis Bullosa (RDEB), Inflammation\u003c\/td\u003e\n\u003ctd\u003eExpected BLA and MAA Filing in \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDN-TNF Platform (XPro™\/XPro1595)\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's Disease (AD), Neuroinflammation\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Net Loss Attributable to Common Stockholders: \u003cstrong\u003e$6.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINKmune™\u003c\/td\u003e\n\u003ctd\u003eCancer (Minimal Residual Disease)\u003c\/td\u003e\n\u003ctd\u003eCommon Shares Outstanding: \u003cstrong\u003e~26.6 million\u003c\/strong\u003e (as of October 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Company Financial Health\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Engine Foundation\u003c\/td\u003e\n\u003ctd\u003eCash and Cash Equivalents: \u003cstrong\u003e$27.7 million\u003c\/strong\u003e (as of September 30, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe company's pipeline products include INKmune, INBO3, XPro1595, and LIVNate.\u003c\/p\u003e\n\u003cp\u003eThe Q3 2025 Research and Development expenses totaled approximately \u003cstrong\u003e$4.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Company's Market Capitalization was approximately \u003cstrong\u003e$49.98 million\u003c\/strong\u003e as of December 5, 2025.\u003c\/li\u003e\n\u003cli\u003eTrailing 12-month revenue as of September 30, 2025, was \u003cstrong\u003e$50K\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe last reported stock price was \u003cstrong\u003e$1.91\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Key Scientific Leadership (Dr. Lowdell)\n\u003c\/h2\u003e\n\u003cp\u003eDr. Mark Lowdell is the Chief Scientific Officer (CSO) and inventor of the CORDStrom™ platform.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eCSO and inventor of CORDStrom™, which has a planned Biologics License Application (BLA) submission targeted for early 2026 for Recessive Dystrophic Epidermolysis Bullosa (RDEB).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eInventor in senior leadership role for core asset.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eSpecific historical knowledge and scientific intuition are difficult to replicate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eActively presenting updates on CORDStrom™ and INKmune® platform, which is in trials for metastatic castration-resistant prostate cancer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained\u003c\/td\u003e\n\u003ctd\u003eKey personnel with unique historical knowledge are hard to poach or replace effectively.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional statistical and financial data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eINKmune® Phase I portion completed for the third and highest dose cohort as of Q1 2025.\u003c\/li\u003e\n\u003cli\u003eThe Company reported a net loss attributable to common stockholders of approximately \u003cstrong\u003e$9.7 million\u003c\/strong\u003e for the quarter ended March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses totaled approximately \u003cstrong\u003e$7.6 million\u003c\/strong\u003e for the quarter ended March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eNet loss attributable to common stockholders for the quarter ended June 30, 2025, was approximately \u003cstrong\u003e$24.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents totaled approximately \u003cstrong\u003e$33.4 million\u003c\/strong\u003e as of June 30, 2025, funding operations into \u003cstrong\u003eQ3 of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eYear ended December 31, 2024, net loss was \u003cstrong\u003e$42.1 million\u003c\/strong\u003e, with R\u0026amp;D expenses of \u003cstrong\u003e$33.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eINmune Bio, Inc. (INMB) - VRIO Analysis: Cash Runway and Liquidity Management\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cash and cash equivalents position as of September 30, 2025, was reported at approximately \u003cstrong\u003e$27.7 million\u003c\/strong\u003e. Based on the current operating plan, management believes this cash is sufficient to fund operations into \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMany clinical-stage biotechs maintain cash reserves; however, the specific projection of funding operations into \u003cstrong\u003eQ4 2026\u003c\/strong\u003e based on the \u003cstrong\u003e$27.7 million\u003c\/strong\u003e balance is a key metric for assessing immediate operational flexibility.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe current cash position of \u003cstrong\u003e$27.7 million\u003c\/strong\u003e is a verifiable fact at a specific point in time, making the current quantum easy to imitate through subsequent capital raises by competitors.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement is demonstrating expense control, evidenced by Research and Development (R\u0026amp;D) expenses decreasing to approximately \u003cstrong\u003e$4.9 million\u003c\/strong\u003e for the quarter ended September 30, 2025, compared to approximately \u003cstrong\u003e$10.1 million\u003c\/strong\u003e for the comparable period in 2024. General and administrative expenses were approximately \u003cstrong\u003e$2.5 million\u003c\/strong\u003e in Q3 2025 versus approximately \u003cstrong\u003e$2.2 million\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (USD)\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2025\u003c\/th\u003e\n\u003cth\u003eQ3 Ended September 30, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents (Period End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and Development Expenses (Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeneral and Administrative Expenses (Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to Common Stockholders (Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommon Shares Outstanding (As of Date)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~26.6 million\u003c\/strong\u003e (Oct 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e~22.2 million\u003c\/strong\u003e (Oct 31, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe current liquidity provides a necessary runway to execute near-term milestones, such as presenting additional \u003cstrong\u003eCORDStrom\u003c\/strong\u003e data in \u003cstrong\u003eQ4 2025\u003c\/strong\u003e and filing a Marketing Authorization Application (MAA) in mid-\u003cstrong\u003e2026\u003c\/strong\u003e, but this advantage is temporary as cash is deployed.\u003c\/p\u003e\n\n\u003cp\u003eFinance: Q4 2025 Cash Flow Projection Basis (Informing Factors):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D spend is expected to support advancement of three platforms: \u003cstrong\u003eCORDStrom\u003c\/strong\u003e, \u003cstrong\u003eXPro1595\u003c\/strong\u003e, and \u003cstrong\u003eINKmune\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eUpcoming milestones driving potential Q4 2025 spend include presenting additional \u003cstrong\u003eCORDStrom\u003c\/strong\u003e data and releasing imaging data from the Phase 2 \u003cstrong\u003eXPro1595\u003c\/strong\u003e MINDFuL trial.\u003c\/li\u003e\n\u003cli\u003eFinal data analysis for the \u003cstrong\u003eINKmune\u003c\/strong\u003e CARE-PC trial is underway, with release expected in \u003cstrong\u003eQ4 2026\u003c\/strong\u003e, implying ongoing analysis costs.\u003c\/li\u003e\n\u003cli\u003eThe company is on track to request an End of Phase 2 meeting with the FDA for \u003cstrong\u003eXPro1595\u003c\/strong\u003e, anticipated in \u003cstrong\u003eQ1, 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516187435157,"sku":"inmb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/inmb-vrio-analysis.png?v=1740184678","url":"https:\/\/dcf-model.com\/products\/inmb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}